 Elizabeth Goldberg
Concepts (231)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Emergency Service, Hospital | 33 | 2025 | 2054 | 5.640 |
Why?
| | Patient Transfer | 7 | 2024 | 165 | 3.410 |
Why?
| | Accidental Falls | 7 | 2024 | 183 | 3.050 |
Why?
| | Nursing Homes | 4 | 2024 | 167 | 2.310 |
Why?
| | Dementia | 3 | 2024 | 252 | 1.340 |
Why?
| | Documentation | 2 | 2024 | 189 | 1.300 |
Why?
| | Aged | 36 | 2025 | 23798 | 1.280 |
Why?
| | Telemedicine | 4 | 2022 | 852 | 1.260 |
Why?
| | Potentially Inappropriate Medication List | 3 | 2024 | 16 | 1.250 |
Why?
| | Hypertension | 6 | 2019 | 1293 | 1.240 |
Why?
| | Medicare | 4 | 2023 | 747 | 1.160 |
Why?
| | Blood Pressure Determination | 4 | 2017 | 156 | 1.110 |
Why?
| | Medicare Part C | 2 | 2018 | 29 | 1.040 |
Why?
| | Aged, 80 and over | 18 | 2025 | 7593 | 0.980 |
Why?
| | Physicians | 4 | 2022 | 904 | 0.900 |
Why?
| | Patient Acceptance of Health Care | 2 | 2021 | 809 | 0.890 |
Why?
| | Medication Adherence | 3 | 2024 | 471 | 0.870 |
Why?
| | Emergency Medical Services | 5 | 2023 | 548 | 0.810 |
Why?
| | Patient Discharge | 4 | 2022 | 895 | 0.810 |
Why?
| | Caregivers | 2 | 2021 | 872 | 0.810 |
Why?
| | Transitional Care | 1 | 2023 | 40 | 0.800 |
Why?
| | Pharmacists | 2 | 2023 | 260 | 0.770 |
Why?
| | Geriatrics | 2 | 2024 | 88 | 0.760 |
Why?
| | Ethanol | 2 | 2024 | 608 | 0.760 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 2 | 2024 | 252 | 0.750 |
Why?
| | Humans | 58 | 2025 | 137514 | 0.720 |
Why?
| | Home Care Services | 1 | 2024 | 254 | 0.700 |
Why?
| | Qualitative Research | 4 | 2024 | 1361 | 0.690 |
Why?
| | Hospitalization | 5 | 2023 | 2197 | 0.680 |
Why?
| | Pandemics | 4 | 2022 | 1619 | 0.670 |
Why?
| | Coinfection | 1 | 2021 | 137 | 0.670 |
Why?
| | Professional-Patient Relations | 1 | 2021 | 145 | 0.660 |
Why?
| | Quarantine | 1 | 2020 | 29 | 0.660 |
Why?
| | Rhode Island | 4 | 2022 | 27 | 0.650 |
Why?
| | Preliminary Data | 1 | 2019 | 11 | 0.650 |
Why?
| | Coronavirus | 1 | 2020 | 45 | 0.640 |
Why?
| | Referral and Consultation | 3 | 2020 | 780 | 0.630 |
Why?
| | Smartphone | 1 | 2020 | 91 | 0.630 |
Why?
| | Social Media | 1 | 2022 | 157 | 0.620 |
Why?
| | Medication Therapy Management | 1 | 2019 | 75 | 0.600 |
Why?
| | Physicians, Primary Care | 1 | 2021 | 236 | 0.580 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2019 | 85 | 0.580 |
Why?
| | Quality Indicators, Health Care | 2 | 2018 | 310 | 0.570 |
Why?
| | Skilled Nursing Facilities | 2 | 2023 | 131 | 0.550 |
Why?
| | Mobile Applications | 1 | 2020 | 180 | 0.540 |
Why?
| | Disease Outbreaks | 1 | 2020 | 376 | 0.530 |
Why?
| | Male | 30 | 2025 | 67718 | 0.520 |
Why?
| | Inventions | 1 | 2016 | 19 | 0.510 |
Why?
| | Renal Colic | 1 | 2016 | 3 | 0.510 |
Why?
| | Benchmarking | 1 | 2017 | 184 | 0.500 |
Why?
| | Coronavirus Infections | 2 | 2021 | 359 | 0.490 |
Why?
| | Female | 30 | 2025 | 73162 | 0.490 |
Why?
| | Prochlorperazine | 2 | 2025 | 7 | 0.470 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 368 | 0.460 |
Why?
| | Quality Assurance, Health Care | 1 | 2017 | 324 | 0.460 |
Why?
| | Health Expenditures | 1 | 2016 | 185 | 0.460 |
Why?
| | Analgesia | 1 | 2016 | 110 | 0.450 |
Why?
| | Inappropriate Prescribing | 3 | 2024 | 55 | 0.440 |
Why?
| | Mortality | 1 | 2016 | 357 | 0.430 |
Why?
| | Length of Stay | 1 | 2019 | 1210 | 0.430 |
Why?
| | Anxiety | 1 | 2021 | 1041 | 0.420 |
Why?
| | Altitude Sickness | 2 | 2025 | 152 | 0.410 |
Why?
| | Attitude of Health Personnel | 1 | 2021 | 1169 | 0.410 |
Why?
| | United States | 11 | 2024 | 14696 | 0.390 |
Why?
| | Blood Pressure | 2 | 2019 | 1776 | 0.390 |
Why?
| | Hospitals | 1 | 2017 | 678 | 0.390 |
Why?
| | Benzodiazepines | 2 | 2024 | 153 | 0.380 |
Why?
| | Wounds and Injuries | 2 | 2024 | 752 | 0.380 |
Why?
| | Patient Readmission | 1 | 2017 | 696 | 0.370 |
Why?
| | Continuity of Patient Care | 2 | 2024 | 279 | 0.350 |
Why?
| | Atrioventricular Block | 1 | 2010 | 36 | 0.320 |
Why?
| | Mass Screening | 2 | 2021 | 1264 | 0.320 |
Why?
| | Surveys and Questionnaires | 4 | 2024 | 5772 | 0.320 |
Why?
| | Lyme Disease | 1 | 2010 | 58 | 0.310 |
Why?
| | Geriatric Assessment | 3 | 2021 | 214 | 0.310 |
Why?
| | Emergency Medicine | 3 | 2021 | 224 | 0.310 |
Why?
| | Quality of Life | 2 | 2024 | 2870 | 0.310 |
Why?
| | Middle Aged | 11 | 2025 | 33355 | 0.280 |
Why?
| | Retrospective Studies | 7 | 2025 | 15628 | 0.260 |
Why?
| | Adult | 11 | 2025 | 37821 | 0.260 |
Why?
| | Risk Adjustment | 2 | 2017 | 78 | 0.260 |
Why?
| | Head and Neck Neoplasms | 2 | 2022 | 617 | 0.240 |
Why?
| | Tablets | 1 | 2024 | 36 | 0.220 |
Why?
| | Cough | 2 | 2022 | 121 | 0.220 |
Why?
| | Delirium | 1 | 2025 | 85 | 0.220 |
Why?
| | Electronic Health Records | 2 | 2024 | 1040 | 0.220 |
Why?
| | Pilot Projects | 2 | 2019 | 1703 | 0.210 |
Why?
| | Anaphylaxis | 1 | 2025 | 105 | 0.210 |
Why?
| | Narration | 1 | 2024 | 58 | 0.210 |
Why?
| | Reproductive Health Services | 2 | 2020 | 19 | 0.210 |
Why?
| | Eligibility Determination | 1 | 2023 | 66 | 0.200 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 116 | 0.200 |
Why?
| | Delivery of Health Care | 2 | 2020 | 948 | 0.200 |
Why?
| | Pharmacies | 1 | 2023 | 37 | 0.200 |
Why?
| | Pharmacy | 1 | 2023 | 32 | 0.200 |
Why?
| | Reproducibility of Results | 3 | 2025 | 3292 | 0.200 |
Why?
| | Tumor Escape | 1 | 2022 | 42 | 0.190 |
Why?
| | Quality of Health Care | 3 | 2024 | 627 | 0.190 |
Why?
| | Delphi Technique | 1 | 2024 | 273 | 0.190 |
Why?
| | Cannabinoids | 1 | 2024 | 161 | 0.190 |
Why?
| | Pharmaceutical Services | 1 | 2023 | 84 | 0.190 |
Why?
| | Comprehension | 1 | 2024 | 182 | 0.190 |
Why?
| | Internet | 2 | 2024 | 656 | 0.190 |
Why?
| | Cross-Sectional Studies | 3 | 2024 | 5427 | 0.190 |
Why?
| | Prevalence | 3 | 2024 | 2719 | 0.180 |
Why?
| | Drug Prescriptions | 1 | 2023 | 251 | 0.180 |
Why?
| | Primary Health Care | 2 | 2022 | 1756 | 0.180 |
Why?
| | Longevity | 1 | 2022 | 165 | 0.170 |
Why?
| | Health Services for Transgender Persons | 1 | 2020 | 3 | 0.170 |
Why?
| | Technology | 1 | 2021 | 95 | 0.170 |
Why?
| | 4-Nitroquinoline-1-oxide | 1 | 2020 | 10 | 0.170 |
Why?
| | Severe Acute Respiratory Syndrome | 1 | 2020 | 14 | 0.170 |
Why?
| | Asthma | 1 | 2013 | 2290 | 0.170 |
Why?
| | Goals | 1 | 2021 | 168 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 1 | 2024 | 403 | 0.160 |
Why?
| | Severity of Illness Index | 2 | 2021 | 2838 | 0.160 |
Why?
| | Independent Living | 1 | 2021 | 102 | 0.160 |
Why?
| | Risk Assessment | 2 | 2021 | 3439 | 0.160 |
Why?
| | Triage | 2 | 2025 | 221 | 0.160 |
Why?
| | Mind-Body Therapies | 1 | 2019 | 7 | 0.160 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 1 | 2020 | 95 | 0.160 |
Why?
| | Sexism | 1 | 2020 | 62 | 0.160 |
Why?
| | Asymptomatic Diseases | 2 | 2016 | 87 | 0.160 |
Why?
| | Medicaid | 1 | 2023 | 436 | 0.160 |
Why?
| | Contraception Behavior | 1 | 2020 | 102 | 0.160 |
Why?
| | Single-Blind Method | 1 | 2019 | 288 | 0.150 |
Why?
| | Physical Therapists | 1 | 2019 | 62 | 0.150 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1047 | 0.150 |
Why?
| | Risk Factors | 3 | 2023 | 10356 | 0.150 |
Why?
| | New England | 1 | 2017 | 32 | 0.140 |
Why?
| | Medical History Taking | 1 | 2017 | 119 | 0.140 |
Why?
| | Physical Therapy Modalities | 1 | 2020 | 309 | 0.140 |
Why?
| | Women's Health | 1 | 2020 | 371 | 0.140 |
Why?
| | Betacoronavirus | 1 | 2020 | 268 | 0.130 |
Why?
| | Fee-for-Service Plans | 1 | 2017 | 86 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2022 | 683 | 0.130 |
Why?
| | Fear | 1 | 2020 | 354 | 0.130 |
Why?
| | Sleep Initiation and Maintenance Disorders | 1 | 2019 | 165 | 0.130 |
Why?
| | Young Adult | 4 | 2025 | 13243 | 0.130 |
Why?
| | Sexual and Gender Minorities | 1 | 2020 | 213 | 0.130 |
Why?
| | Secondary Prevention | 1 | 2017 | 233 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2024 | 1002 | 0.130 |
Why?
| | Colic | 1 | 2016 | 8 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 531 | 0.120 |
Why?
| | Health Services Accessibility | 2 | 2020 | 976 | 0.120 |
Why?
| | Prospective Studies | 2 | 2019 | 7598 | 0.120 |
Why?
| | Adolescent | 4 | 2025 | 21555 | 0.120 |
Why?
| | Needs Assessment | 1 | 2017 | 368 | 0.120 |
Why?
| | Cohort Studies | 2 | 2025 | 5730 | 0.120 |
Why?
| | Cognitive Dysfunction | 1 | 2020 | 386 | 0.120 |
Why?
| | Biomedical Research | 1 | 2021 | 689 | 0.120 |
Why?
| | Choice Behavior | 1 | 2016 | 174 | 0.120 |
Why?
| | Forecasting | 1 | 2016 | 386 | 0.110 |
Why?
| | Cancer Survivors | 1 | 2019 | 280 | 0.110 |
Why?
| | Monitoring, Physiologic | 1 | 2016 | 267 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2039 | 0.100 |
Why?
| | Self Report | 1 | 2017 | 831 | 0.100 |
Why?
| | Infant | 3 | 2017 | 9467 | 0.100 |
Why?
| | Case-Control Studies | 1 | 2020 | 3546 | 0.100 |
Why?
| | Pain Management | 1 | 2016 | 363 | 0.100 |
Why?
| | Child, Preschool | 3 | 2017 | 11097 | 0.100 |
Why?
| | Acute Disease | 2 | 2025 | 1008 | 0.090 |
Why?
| | Kidney Diseases | 1 | 2016 | 407 | 0.090 |
Why?
| | Developing Countries | 1 | 2013 | 305 | 0.090 |
Why?
| | Sepsis | 1 | 2017 | 611 | 0.090 |
Why?
| | Sex Factors | 1 | 2017 | 2074 | 0.090 |
Why?
| | Ceftriaxone | 1 | 2010 | 20 | 0.080 |
Why?
| | Double-Blind Method | 2 | 2025 | 1987 | 0.080 |
Why?
| | Child | 3 | 2017 | 22037 | 0.080 |
Why?
| | Anti-Asthmatic Agents | 1 | 2013 | 393 | 0.080 |
Why?
| | Pain | 1 | 2016 | 836 | 0.080 |
Why?
| | Reproductive Health | 2 | 2020 | 91 | 0.080 |
Why?
| | Quality Improvement | 1 | 2017 | 1161 | 0.080 |
Why?
| | Mutation | 1 | 2020 | 3964 | 0.070 |
Why?
| | Oxygen | 1 | 2013 | 943 | 0.070 |
Why?
| | Communication | 1 | 2013 | 874 | 0.070 |
Why?
| | Pneumonia | 1 | 2013 | 638 | 0.070 |
Why?
| | Electrocardiography | 1 | 2010 | 632 | 0.070 |
Why?
| | Breast Neoplasms | 1 | 2019 | 2249 | 0.070 |
Why?
| | Infant, Newborn | 1 | 2017 | 6059 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1486 | 0.060 |
Why?
| | Postoperative Complications | 1 | 2017 | 2641 | 0.060 |
Why?
| | Mountaineering | 1 | 2025 | 40 | 0.060 |
Why?
| | Parents | 1 | 2013 | 1363 | 0.060 |
Why?
| | Epinephrine | 1 | 2025 | 145 | 0.060 |
Why?
| | Substance Abuse Detection | 1 | 2024 | 90 | 0.050 |
Why?
| | Receptors, Interferon | 1 | 2022 | 51 | 0.050 |
Why?
| | Retroelements | 1 | 2022 | 47 | 0.050 |
Why?
| | Long-Term Care | 1 | 2023 | 100 | 0.050 |
Why?
| | Administration, Oral | 1 | 2024 | 814 | 0.050 |
Why?
| | Internationality | 2 | 2013 | 155 | 0.050 |
Why?
| | Emergency Treatment | 1 | 2023 | 117 | 0.050 |
Why?
| | Trauma Centers | 1 | 2024 | 422 | 0.050 |
Why?
| | Interferons | 1 | 2022 | 199 | 0.040 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2021 | 129 | 0.040 |
Why?
| | Decision Trees | 1 | 2021 | 94 | 0.040 |
Why?
| | Consensus | 1 | 2024 | 685 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 210 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2025 | 1950 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2025 | 10821 | 0.040 |
Why?
| | Anti-Bacterial Agents | 1 | 2010 | 1800 | 0.040 |
Why?
| | Fever | 1 | 2021 | 307 | 0.040 |
Why?
| | Carcinogens | 1 | 2020 | 123 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1465 | 0.040 |
Why?
| | Chromatin | 1 | 2022 | 524 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 696 | 0.040 |
Why?
| | Research | 1 | 2021 | 446 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2022 | 710 | 0.030 |
Why?
| | Age Factors | 1 | 2025 | 3301 | 0.030 |
Why?
| | DNA Methylation | 1 | 2022 | 644 | 0.030 |
Why?
| | Pregnancy | 2 | 2020 | 6745 | 0.030 |
Why?
| | Histones | 1 | 2022 | 641 | 0.030 |
Why?
| | Transgender Persons | 1 | 2020 | 180 | 0.030 |
Why?
| | Feasibility Studies | 1 | 2019 | 950 | 0.030 |
Why?
| | Databases, Factual | 1 | 2021 | 1351 | 0.030 |
Why?
| | Research Design | 1 | 2021 | 1116 | 0.030 |
Why?
| | Colorado | 1 | 2025 | 4521 | 0.030 |
Why?
| | Patient Satisfaction | 1 | 2019 | 657 | 0.030 |
Why?
| | Mice | 2 | 2022 | 17843 | 0.030 |
Why?
| | Time Factors | 1 | 2024 | 6817 | 0.030 |
Why?
| | Rwanda | 1 | 2013 | 27 | 0.030 |
Why?
| | Respiratory Rate | 1 | 2013 | 21 | 0.030 |
Why?
| | Hospitals, Rural | 1 | 2013 | 39 | 0.030 |
Why?
| | Registries | 1 | 2021 | 2021 | 0.020 |
Why?
| | Area Under Curve | 1 | 2013 | 316 | 0.020 |
Why?
| | Antihypertensive Agents | 1 | 2016 | 493 | 0.020 |
Why?
| | Disease Progression | 1 | 2020 | 2755 | 0.020 |
Why?
| | ROC Curve | 1 | 2013 | 547 | 0.020 |
Why?
| | Health Resources | 1 | 2012 | 122 | 0.020 |
Why?
| | Decision Support Techniques | 1 | 2013 | 419 | 0.020 |
Why?
| | Animals | 2 | 2022 | 37011 | 0.020 |
Why?
|
|
Goldberg's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|